Home/ Stocks/ CRBP

Corbus Pharmaceuticals Holdings, Inc.

CRBP XNAS

$10.17 +0.03 (+0.31%) ▲ 15-min delayed

Open

$9.74

High

$10.23

Low

$9.74

Volume

357.1K

Market Cap

$180.46M

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 36 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$1.40M	$-22,969,000	$-1.23
FY 2025	$5.53M	$-78,537,000	$-5.90
Q3 2025	$1.13M	$-23,342,000	$-1.90
Q2 2025	$1.31M	$-17,662,000	$-1.44

Related Market News

No specific coverage for CRBP yet. Check out our latest market news or earnings calendar.

Get CRBP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Corbus Pharmaceuticals Holdings, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.